Bio-Rad Laboratories Yönetim

Yönetim kriter kontrolleri 3/4

Bio-Rad Laboratories CEO'su Norman Schwartz, Jan2003 tarihinde atandı, in görev süresi 21.83 yıldır. in toplam yıllık tazminatı $ 7.46M olup, şirket hissesi ve opsiyonları dahil olmak üzere 13.9% maaş ve 86.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4.34% ine doğrudan sahiptir ve bu hisseler € 381.71M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 7.6 yıldır.

Anahtar bilgiler

Norman Schwartz

İcra Kurulu Başkanı

US$7.5m

Toplam tazminat

CEO maaş yüzdesi	13.9%
CEO görev süresi	21.8yrs
CEO sahipliği	4.3%
Yönetim ortalama görev süresi	3.4yrs
Yönetim Kurulu ortalama görev süresi	7.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Norman Schwartz'un ücretlendirmesi Bio-Rad Laboratories'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$779m
Jun 30 2024	n/a	n/a	-US$1b
Mar 31 2024	n/a	n/a	-US$322m
Dec 31 2023	US$7m	US$1m	-US$637m
Sep 30 2023	n/a	n/a	-US$159m
Jun 30 2023	n/a	n/a	-US$428m
Mar 31 2023	n/a	n/a	-US$191m
Dec 31 2022	US$8m	US$1m	-US$4b
Sep 30 2022	n/a	n/a	-US$6b
Jun 30 2022	n/a	n/a	-US$2b
Mar 31 2022	n/a	n/a	-US$91m
Dec 31 2021	US$9m	US$988k	US$4b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$8m	US$987k	US$4b
Sep 30 2020	n/a	n/a	US$4b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$7m	US$950k	US$2b
Sep 30 2019	n/a	n/a	US$377m
Jun 30 2019	n/a	n/a	US$905m
Mar 31 2019	n/a	n/a	US$574m
Dec 31 2018	US$8m	US$942k	US$366m
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$767m
Dec 31 2017	US$5m	US$922k	US$122m

Tazminat ve Piyasa: Norman 'nin toplam tazminatı ($USD 7.46M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.58M ).

Tazminat ve Kazançlar: Norman 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Norman Schwartz (74 yo)

21.8yrs

Görev süresi

US$7,463,878

Tazminat

Mr. Norman D. Schwartz was Principal Financial Officer of Bio-Rad Laboratories, Inc. since February 9, 2024 until April 15, 2024 and served as its Interim CFO until February 9, 2024. He serves as an Indepe...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Norman Schwartz	Chairman & CEO	21.8yrs	US$7.46m	4.34% € 381.7m
Jonathan DiVincenzo	President & COO	less than a year	Veri yok	Veri yok
Roop Lakkaraju	Executive VP & CFO	less than a year	Veri yok	Veri yok
Tania DeVilliers	Senior Director	3.4yrs	Veri yok	0.00020% € 17.6k
Yong Chung	Vice President of Investor Relations	no data	Veri yok	Veri yok
Matthew Werner	Senior Vice President and Chief Compliance & Privacy Officer	no data	Veri yok	Veri yok
Courtney Enloe	Executive VP	less than a year	Veri yok	Veri yok
Colleen Corey	Executive Vice President of Global Human Resources	10.6yrs	Veri yok	0.066% € 5.8m
Michael Crowley	Executive Vice President of Global Commercial Operations	9.9yrs	US$2.68m	0.029% € 2.6m
Lee Boyd	Senior Vice President of Global Commercial Operations - Asia Pacific	no data	Veri yok	Veri yok
James Barry	Executive VP & President of Life Science Group	no data	Veri yok	0.00053% € 46.6k
Kurt DeLanghe	Senior Vice President of Global Commercial Operations of Europe	no data	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: BUWA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Norman Schwartz	Chairman & CEO	29.8yrs	US$7.46m	4.34% € 381.7m
Gregory Hinckley	Lead Independent Director	7.6yrs	US$199.25k	0.0018% € 157.5k
Alice Schwartz	Director Emeritus	2.6yrs	US$40.18k	11.46% € 1.0b
Jeffrey Edwards	Independent Director	7.6yrs	US$190.00k	Veri yok
Arnold Pinkston	Independent Director	7.6yrs	US$178.75k	Veri yok
Melinda Pei	Independent Director	7.6yrs	US$195.00k	Veri yok
Allison Schwartz	Director	2.6yrs	Veri yok	0.019% € 1.6m

7.6yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BUWA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.6 yıldır).

Bio-Rad Laboratories Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Bio-Rad Laboratories, Inc. Announces Executive Changes

Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024

Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group

Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 23, 2024

Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024

Recent updates

Third quarter 2024 earnings released: EPS: US$23.37 (vs US$3.65 in 3Q 2023)

Bio-Rad Laboratories, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Bio-Rad Laboratories, Inc.(NYSE:BIO) dropped from FTSE All-World Index (USD)

Bio-Rad Laboratories, Inc. Announces Executive Changes

Second quarter 2024 earnings released: US$76.26 loss per share (vs US$39.59 loss in 2Q 2023)

Bio-Rad Laboratories, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024

First quarter 2024 earnings released: EPS: US$13.46 (vs US$2.33 in 1Q 2023)

New major risk - Revenue and earnings growth

Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group

Bio-Rad Laboratories, Inc. to Report Q1, 2024 Results on May 07, 2024

Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 23, 2024

Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024

Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial Officer

Full year 2023 earnings released: US$21.82 loss per share (vs US$122 loss in FY 2022)

Bio-Rad Laboratories, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Bio-Rad Laboratories, Inc. Announces Resignation of Dara Grantham Wright as Executive Vice-President and President, Effective January 12, 2024

Third quarter 2023 earnings released: EPS: US$3.65 (vs US$5.52 loss in 3Q 2022)

Bio-Rad Laboratories, Inc. Announces Resignation of Ilan Daskal, Chief Financial Officer, Effective November 6, 2023

Bio-Rad Laboratories, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Revenue and earnings growth

Bio-Rad Laboratories, Inc. Announces Executive Changes, Effective September 18, 2023

Bio-Rad Laboratories, Inc. Updates Its Financial Outlook for Full-Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$39.59 loss per share (vs US$31.12 loss in 2Q 2022)

Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Senior VP & Chief Accounting Officer recently sold €68k worth of stock

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: EPS: US$2.33 (vs US$113 loss in 1Q 2022)

Executive VP recently sold €344k worth of stock

Full year 2022 earnings released: US$122 loss per share (vs US$142 profit in FY 2021)

Bio-Rad Laboratories, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Senior VP & Chief Accounting Officer recently sold €157k worth of stock

Now 21% undervalued after recent price drop

Third quarter 2022 earnings released: US$5.52 loss per share (vs US$132 profit in 3Q 2021)

Bio-Rad Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Bio-Rad Laboratories, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Senior VP & Chief Accounting Officer recently sold €274k worth of stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) agreed to acquire Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. (WSE:SCP) for $100 million.

Bio-Rad Laboratories, Inc. (NYSE:BIO) agreed to acquire Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. (WSE:SCP) for $100 million.

Second quarter 2022 earnings released: US$31.12 loss per share (vs US$30.71 profit in 2Q 2021)

Bio-Rad Laboratories, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Now 23% undervalued after recent price drop

Bio-Rad Laboratories, Inc.(NYSE:BIO) dropped from Russell 1000 Value-Defensive Index

High number of new directors

First quarter 2022 earnings released: US$113 loss per share (vs US$32.77 profit in 1Q 2021)

Insufficient new directors

Bio-Rad Laboratories, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 26, 2022

Bio-Rad Laboratories, Inc. Announces Board Changes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS US$132 (vs US$44.24 in 3Q 2020)

Executive VP & CFO recently sold €186k worth of stock

Insider recently sold €404k worth of stock

Executive VP & CFO recently sold €572k worth of stock

Second quarter 2021 earnings released: EPS US$30.71 (vs US$32.59 in 2Q 2020)

Bio-Rad Launches Its Prevalence Ddpcr Sars-Cov-2 Wastewater Quantification Kit for Covid-19 Wastewater Testing

First quarter 2021 earnings released: EPS US$32.75 (vs US$22.97 in 1Q 2020)

Executive VP recently sold €276k worth of stock

Full year 2020 earnings released: EPS US$128 (vs US$58.93 in FY 2019)

Revenue beats expectations

New 90-day high: €535

Bio-Rad Laboratories, Inc. to Report Q4, 2020 Results on Feb 11, 2021

Insider recently sold €179k worth of stock

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

New 90-day high: €490